Seller record · Telehealth service

Strut Health

Fails 2 of 8 criteria. S3, pharmacy identification: Medication is said to come from a licensed United States pharmacy, and no filling facility is named anywhere on the site. 1 more criterion also fails; see the table below.

At a glance

Strut HealthTelehealth service

6/8criteria passed
Price
Injectable semaglutide $129 a monthly vial
Sells
compounded semaglutide, compounded tirzepatide, sermorelin, and 5 more
FDA letters
1 on file

Partner link. The site earns a commission on care started through it. Funding

Visit Strut HealthSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded GLP-1 drugs, peptides and men's health medications. An FDA warning letter names the operating entity.

Operating entity Strut Health, LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSStrut Health's how it works page
S2Prescription gatingPASSStrut Health's intro page
S3Pharmacy identificationFAILStrut Health's our story page
S4Compounding disclosurePASSStrut Health's semaglutide page
S5Analytical documentationFAILStrut Health's sitemap page
S6Business addressPASSStrut Health's website
S7Price disclosurePASSStrut Health's semaglutide page
S8Enforcement statusPASSFDA's website; FDA warning letter 721448

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed United States physician reviews the profile and prescribes if clinically appropriate; the founder is named as Simal Patel, MD.Source: Strut Health's how it works page.
S2PASSThe medical questions introduction inside checkout stops the order.Source: Strut Health's intro page.
S3FAILMedication is said to come from a licensed United States pharmacy, and no filling facility is named anywhere on the site.Source: Strut Health's our story page.
S4PASSCompound prescription products have not been tested or approved by the FDA, printed on the semaglutide product page.Source: Strut Health's semaglutide page.
S5FAILNo certificate, lot report or test document appears on the product page, in the FAQ or anywhere else on the site.Source: Strut Health's sitemap page.
S6PASS701 Commerce St, Dallas, Texas 75202, printed in the footer and matching the address on the warning letter.Source: Strut Health's website.
S7PASSInjectable semaglutide at 129 dollars for a monthly vial, and oral semaglutide at 199 dollars for a thirty-day supply.Source: Strut Health's semaglutide page.
S8PASSFDA warning letter 721448, February 2026, names Strut Health, LLC dba Strut at 701 Commerce St, Dallas, Texas, alleging that claims about its compounded semaglutide and tirzepatide products, including the representation that Strut is the compounder, are false or misleading. No close-out letter appears in the index. No FDA action has halted the business, and the storefront still trades.Source: FDA's website; FDA warning letter 721448.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sermorelin, NAD+, enclomiphene, tadalafil, tretinoin, minoxidil.

Enforcement documents on file: 1 warning letter

FDA warning letter 721448, issued February 2026, to Strut Health, LLC dba StrutPictured labels identify Strut as the compounder of semaglutide and tirzepatide products when it is not, and the site claims the same active ingredient as the brand medications under headings such as Generic Zepbound.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Partner link. The site earns a commission on care started through it. Funding.

Visit Strut Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.